Researchers from the Community for Open Antimicrobial Drug Discovery (CO-ADD) have been awarded almost $1 million to develop a new antibiotic that could treat life-threatening bacterial infections resistant to all known antibiotics.
From the DRIVE-AB conference in Brussels to talking Natural Product Chemistry at RACI's symposium in Sydney. It has been a busy September 2017. CO-ADD’s Program Coordinator Dr Mark Blaskovich reports back.
CO-ADD's Dr Karl Hansford has just returned from Boston for the 2017 ASM/ESCMID conference. Read his latest blog post below summarising all the conference activities.